IRON

#1698
Disc Medicine, Inc. - Common Stock
78.6 7 USD
0.00%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
78.37
78.79
Intervallo Annuale
40.00
99.50
Variazione giornaliera
+0.03%
Variazione Mensile
+2.17%
Variazione di 6 mesi
+21.03%
Variazione Annuale
+32.17%
Chiusura Precedente
78.6 5
Open
78.7 1
Minimo
78.3 7
Massimo
78.7 9
Volume
308
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Disc Medicine, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Disc Medicine, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Disc Medicine, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Disc Medicine, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Disc Medicine, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Disc Medicine, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Disc Medicine, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Disc Medicine, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Disc Medicine, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Disc Medicine, Inc. current report, Q1 FY2026
8-K

Disc Medicine, Inc. current report, Q1 FY2026

Full document

Business Context and Reporting Period

Company: Disc Medicine, Inc. (Nasdaq: IRON)
Filing Type: Form 8-K (Current Report)
Report Date: February 26, 2026
Period Covered: Fourth quarter and fiscal year ended December 31, 2025

Disc Medicine, Inc. filed this report to announce its financial results for the fourth quarter and full fiscal year 2025, along with a corporate update. The detailed financial data is contained in a press release furnished as Exhibit 99.1.

Key Financial Metrics

The provided filing text serves as a cover document and does not contain specific numerical data. The following metrics are referenced but not quantified in this text:

  • Revenue: Not provided in filing text.
  • Profit/Loss: Not provided in filing text.
  • Cash Flow: Not provided in filing text.
  • Margins: Not provided in filing text.
  • Debt and Liquidity: Not provided in filing text.

Note: Specific values for revenue, profit, cash flow, and balance sheet items are not present in the Form 8-K text provided; they are located in the attached Exhibit 99.1 press release.

Material Changes

The filing text does not provide specific comparative data or quantify material changes versus the prior comparable period. It only confirms that results for the fourth quarter and fiscal year 2025 were announced.

Guidance, Outlook, and Risks

Management Commentary: The company provided a "corporate update" alongside the financial results, though the specific content of this update is not detailed in the filing text.
Guidance and Outlook: No specific forward-looking guidance or numerical outlook is included in the provided text.
Risks and Contingencies: No specific risks or contingencies are detailed in this filing text.

Investor Verification Checklist

  • Review Exhibit 99.1 (Press Release) for actual revenue, net loss, and cash position figures for Q4 and FY 2025.
  • Verify the specific details of the "corporate update" mentioned in Item 2.02 to understand strategic shifts or pipeline progress.
  • Check for any forward-looking guidance or updated financial projections in the press release.
  • Confirm the company's cash runway and burn rate, as these are critical for a biopharmaceutical entity and are not listed in the 8-K summary.

Notizie